硼替佐米治疗γ/δT细胞淋巴瘤白血病1例并文献复习
|
摘要
目的:评估硼替佐米治疗γ/δT细胞淋巴瘤的效果。方法:分析总结1例γ/δT细胞淋巴瘤白血病的临床资料,并结合文献,对此疾病的特征及诊治情况进行分析。结果:γ/δT细胞淋巴瘤白血病是少见血液病,临床表现危重,死亡率高,目前治疗效果不佳。采用硼替佐米可以缓解临床症状。结论:针对γ/δT细胞淋巴瘤白血病,硼替佐米可以发挥良好的抗肿瘤作用。
Objective: To evaluate the efficacy of bortezomib in the treatment of γ/δT cell lymphoma.Methods: The clinical data of one case of γ/δT cell lymphoma leukemia were analyzed and the characteristics of this disease were analyzed in combination with the literature.Results: γ/δT cell leukemia is a rare hematological disease with severe clinical manifestations and high mortality. Bortezomib was effective to relieve the symptoms.Conclusion: Bortezomib have shown promise in the treatment of γ/δT lymphoma leukemia as antineoplastic agents.
Objective: To evaluate the efficacy of bortezomib in the treatment of γ/δT cell lymphoma.Methods: The clinical data of one case of γ/δT cell lymphoma leukemia were analyzed and the characteristics of this disease were analyzed in combination with the literature.Results: γ/δT cell leukemia is a rare hematological disease with severe clinical manifestations and high mortality. Bortezomib was effective to relieve the symptoms.Conclusion: Bortezomib have shown promise in the treatment of γ/δT lymphoma leukemia as antineoplastic agents.
引文
[1] Visnyei K, Grossbard ML. Hepatosplenicγ/δT-cell lymphoma:an overview[J]. Clin Lymphoma Myeloma Leuk, 2013,13(4):360-369.
[2] Ishida M, Iwai M, Yoshida K, et al. Primary cutaneous B-cell lymphoma with abundant reactive gamma/delta T-cells within the skin lesion and peripheral blood[J]. Int J Clin Exp Pathol, 2014,7(3):1 193-1 199.
[3] Tanase A, Schmitz N, Stein H, et al. Allogeneic and autologous stemcell transplantation for hepatosplenic Tcell lymphoma:a retrospective study of the EBMT Lymphoma Working Party[J]. Leukemia, 2015, 29(3):686-688.
[4] Rashidi A, Cashen AF. Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma[J]. Blood Cancer J, 2015,5(6):e318.
[5] Robak T. Bortezomib in the treatment of mantle cell lymphoma[J]. Future Oncol, 2015,11(20):2 807-2 818.
[6] Gumbs AA,Zain J,Neylon E,et al. Importanceof early splenectomy in patients with hepatosplenic T-cell lymphoma and severe thrombocytopenia[J]. Ann Surg Oncol,2009,16(4):2 014-2 017.
[7] Hambley B, Caimi PF, William BM. Bortezomib for the treatment of mantle cell lymphoma:an update[J].Ther Adv Hematol, 2016,7(4):196-208.
[8] Arkwright R, Pham TM, Zonder JA, et al. The preclinical discoveryand development of bortezomib for the treatment of mantle celllymphoma[J]. Expert Opin Drug Discov, 2017,12(2):225-235.
[9]陈格格,施菊妹,张轶文.套细胞淋巴瘤诊治进展[J].白血病·淋巴瘤,2016,25(10):637-640.Chen GG, Shi JM, Zhang YW. Progress in diagnosis and treatment of mantle cell lymphoma[J]. Journal of Leukemia&Lymphoma, 2016,25(10):637-640.
[10] Lee HJ, Romaguera JE, Feng L, et al. PhaseⅡstudy of bortezomibin combination with cyclophosphamide and rituximab for relapsed orrefractory mantle cell lymphoma[J]. Oncologist,2017,22(5):549-553.
[2] Ishida M, Iwai M, Yoshida K, et al. Primary cutaneous B-cell lymphoma with abundant reactive gamma/delta T-cells within the skin lesion and peripheral blood[J]. Int J Clin Exp Pathol, 2014,7(3):1 193-1 199.
[3] Tanase A, Schmitz N, Stein H, et al. Allogeneic and autologous stemcell transplantation for hepatosplenic Tcell lymphoma:a retrospective study of the EBMT Lymphoma Working Party[J]. Leukemia, 2015, 29(3):686-688.
[4] Rashidi A, Cashen AF. Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma[J]. Blood Cancer J, 2015,5(6):e318.
[5] Robak T. Bortezomib in the treatment of mantle cell lymphoma[J]. Future Oncol, 2015,11(20):2 807-2 818.
[6] Gumbs AA,Zain J,Neylon E,et al. Importanceof early splenectomy in patients with hepatosplenic T-cell lymphoma and severe thrombocytopenia[J]. Ann Surg Oncol,2009,16(4):2 014-2 017.
[7] Hambley B, Caimi PF, William BM. Bortezomib for the treatment of mantle cell lymphoma:an update[J].Ther Adv Hematol, 2016,7(4):196-208.
[8] Arkwright R, Pham TM, Zonder JA, et al. The preclinical discoveryand development of bortezomib for the treatment of mantle celllymphoma[J]. Expert Opin Drug Discov, 2017,12(2):225-235.
[9]陈格格,施菊妹,张轶文.套细胞淋巴瘤诊治进展[J].白血病·淋巴瘤,2016,25(10):637-640.Chen GG, Shi JM, Zhang YW. Progress in diagnosis and treatment of mantle cell lymphoma[J]. Journal of Leukemia&Lymphoma, 2016,25(10):637-640.
[10] Lee HJ, Romaguera JE, Feng L, et al. PhaseⅡstudy of bortezomibin combination with cyclophosphamide and rituximab for relapsed orrefractory mantle cell lymphoma[J]. Oncologist,2017,22(5):549-553.